文献速递乳腺癌

基于MammaPrint的浸润性小叶癌患者生存结局:MINDACT III期试验结果

Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial.
PubMed 文献 · Eur J Cancer · 2025-01-22

本文为MINDACT III期试验的探索性亚组分析,纳入中心病理评估的5929例早期浸润性乳腺癌患者,其中浸润性小叶癌(ILC)487例、无特殊型(NST)4826例。中位随访8.7年,按70基因签名比较ILC与NST的生存结局,结果显示ILC与NST在基因组风险分层下生存估计相似,提示70基因签名对ILC也具有预后价值,可能有助于辅助治疗决策。

要点

  • 70基因签名将16.2%的ILC和39.1%的NST归为基因组高风险,两组按基因组风险总体及亚组生存估计相似。
  • 经典型ILC中10.2%为基因组高风险,ILC变异型中22.8%为基因组高风险。
  • ILC变异型5年无病生存率88.4%(95%CI: 83.1-92.1),低于经典型ILC的93.0%(95%CI: 88.7-95.7)。

核心结论

  • 16%的ILC被70基因签名归为基因组高风险,且生存结局不佳;ILC与NST在基因组低风险或高风险分类下生存估计相似,提示70基因签名在ILC中也有预后价值,可能是辅助治疗决策的临床有用工具。

研究设计与样本

  • MINDACT III期试验的探索性亚组分析,纳入中心病理评估的5929例早期浸润性乳腺癌患者(NST或纯ILC),按70基因签名评估基因组风险、按改良Adjuvant!Online评估临床风险,中位随访8.7年。

主要发现

  • 5313例患者中ILC 487例、NST 4826例;ILC进一步分为经典型ILC 255例和ILC变异型232例。
  • 70基因签名将16.2%的ILC和39.1%的NST归为基因组高风险(gH)。
  • ILC与NST的生存结局按基因组风险总体及亚组比较均显示相似估计。
  • 70基因签名将10.2%的经典型ILC和22.8%的ILC变异型归为gH。
  • ILC变异型5年无病生存率88.4%(95%CI: 83.1-92.1),低于经典型ILC的93.0%(95%CI: 88.7-95.7)。

临床怎么用

  • 原文结论提示70基因签名可能是有助于ILC辅助治疗决策的临床有用工具。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evaluation of the prognostic performance and clinical utility of the MammaPrint 70-gene signature in early-stage invasive lobular carcinoma (ILC) for whom such analyses in a randomized trial is awaited. PATIENTS AND METHODS: Exploratory subgroup analysis of MINDACT trial patients with centrally assessed histology (n = 5929) with invasive breast cancer of no-special-type (NST), or pure ILC. In the trial patients were categorized based on the 70-gene signature for genomic risk and modified Adjuvant!Online for clinical risk. Survival outcomes at 8.7 years median follow-up by 70-gene signature were compared between NST and ILC for Distant Metastasis-Free Survival (DMFS), Disease-Free Survival (DFS) and Overall Survival (OS). RESULTS: 5313 patients were ILC (n = 487) or NST (n = 4826). ILC was further classified into classic ILC (n = 255) or ILC variants (n = 232). The 70-gene signature classified 16.2 % of ILC and 39.1 % of NST as genomic high-risk (gH). Survival outcomes for ILC vs. NST revealed similar estimates according to genomic risk overall and across subsets. The 70-gene signature classified 10.2 % of classic ILC and 22.8 % of ILC variants as gH. 5-yr DFS estimates for ILC variants 88.4 % (95 %CI: 83.1-92.1) was inferior to classic ILC 93.0 % (95 %CI: 88.7-95.7). CONCLUSIONS: Sixteen percent of ILC were classified high genomic risk by the 70-gene signature, with unfavorable survival outcomes. Survival estimates were similar for patients with ILC and NST classified as either low- or high-genomic risk, suggesting that the 70-gene signature also has prognostic value in ILC and may be a clinically useful tool for adjuvant treatment decision-making in ILC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Metzger Filho O, Cardoso F, Poncet C, et al. Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial. Eur J Cancer. 2025. PMID: 39864363. doi:10.1016/j.ejca.2025.115222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。